Cohero Health, an NYC-based digital health company focused on developing connected health tools and technologies to improve respiratory care, has raised $2 million in seed funding. Key investors in the seed round include Zaffre Investments, the investment arm of Blue Cross Blue Shield of Massachusetts, Three Leaf Ventures an affiliate of the Broe Group, Bioadvance, Swanhill Capital and StartUp Health. The company plans to use the funding to scale production of its devices to support large customer deployments, and the full-scale commercial launch of its platform.
Cohero Health’s FDA cleared handheld, wireless spirometer measures critical lung function metrics with the same precision as clinical-grade spirometers. The mobile spirometer pairs with a smartphone or tablet, enabling real-time measurement and reporting. Cohero Health is the first and only company to enable tracking of controller medication, rescue medication and discern lung function in real-time, in an integrated comprehensive model. The company is poised to transform care of asthma and COPD patients through improved self-management, and by empowering clinicians with critical components of optimal respiratory care, knowing how patients are using their medication and how they are responding.
Cohero Health’s platform has successfully been deployed at Mount Sinai Health System and Dartmouth-Hitchcock Medical Center, and plans to announce more partnerships before year’s end. Early results have shown a 2.5 times increase in medication adherence over standard of care, and 100% reduction in hospitalizations.
